Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
- 6 May 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 29 (9), 1875-1881
- https://doi.org/10.1038/leu.2015.115
Abstract
The benefit of azacitidine treatment in survival of high-risk myelodysplastic syndromes (MDS) patients compared with conventional care treatment (CCT) has not been established outside clinical trials. To assess its effectiveness, we compared overall survival (OS) between azacitidine and conventional treatment (CCT) in high-risk MDS patients, excluding those undergoing stem cell transplantation, submitted to the Spanish MDS registry from 2000 to 2013. Several Cox regression and competing risk models, considering azacitidine as a time-dependent covariate, were used to assess survival and acute myeloblastic leukemia (AML) progression. Among 821 patients included, 251 received azacitidine. Median survival was 13.4 (11.8–16) months for azacitidine-treated patients and 12.2 (11–14.1) for patients under CCT (P=0.41). In a multivariate model, age, International prognostic scoring system and lactate dehydrogenase were predictors of OS whereas azacitidine was not (adjusted odds ratio 1.08, 95% confidence interval 0.86–1.35, P=0.49). However, in patients with chromosome 7 abnormalities, a trend toward a better survival was observed in azacitidine-treated patients (median survival 13.3 (11–18) months) compared with CCT (median survival 8.6 (5–10.4) months, P=0.08). In conclusion, our data show that, in spite of a widespread use of azacitidine, there is a lack of improvement in survival over the years. Identification of predicting factors of response and survival is mandatory.Keywords
This publication has 23 references indexed in Scilit:
- Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE studyHaematologica, 2012
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineBlood, 2011
- Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare BeneficiariesJournal of Clinical Oncology, 2010
- Nomenclature Evolution: Changes in the ISCN from the 2005 to the 2009 EditionCytogenetic and Genome Research, 2009
- Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programsBlood, 2008
- Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic SyndromesJournal of Clinical Oncology, 2007
- Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)Leukemia, 2005
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- A non‐parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non‐responder biasStatistics in Medicine, 1984